Sangamo BioSciences affirms full-year revenue, operating expense guidance

|About: Sangamo Therapeutics, Inc. (SGMO)|By:, SA News Editor

Sangamo BioSciences (SGMO) puts up a largely in line quarter (revenues come largely from collabs with Shire and Sigma-Aldrich).

R&D expense for the period was $8.7M, up from $7.6M in Q3 2012.

Full year guidance: Revenues of $20-24M and operating expenses of $46-50M. (PR)